Treatment of primary hyperlipoproteinaemias with a tetralin derivative (Su-13'437).
D000328:Adult; D001797:Blood Protein Electrophoresis; D002784:Cholesterol / Q000097:blood*; D002914:Chylomicrons / Q000097:blood; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009255:Nafenopin / Q000008:administration & dosage / Q000627:therapeutic use; D010919:Placebos; D011422:Propionates / Q000627:therapeutic use*; D013997:Time Factors; D014280:Triglycerides / Q000097:blood*
D002914:Chylomicrons; D000960:Hypolipidemic Agents; D008074:Lipoproteins; D010919:Placebos; D011422:Propionates; D014280:Triglycerides; D009255:Nafenopin; D002784:Cholesterol